# A Simple Blood Test Can Now Detect Polyps and Early Colorectal Cancer
Researchers have developed a blood test that identifies precancerous polyps and early-stage colorectal cancer, offering a less invasive screening option than traditional colonoscopy. The breakthrough addresses a persistent gap in cancer detection and could expand screening rates among populations who avoid colonoscopies due to discomfort or accessibility concerns.
The test detects circulating tumor DNA (ctDNA) in the bloodstream, genetic material shed by abnormal cells in the colon. This approach captures cancer risk at earlier stages than many people currently receive diagnosis. Colorectal cancer remains the second leading cause of cancer deaths in the United States, yet roughly one-third of adults aged 50 to 75 skip recommended screening entirely.
Multiple recent studies validate the blood test's accuracy. Research published in major medical journals shows the test identifies 70 to 80 percent of advanced adenomatous polyps (precancerous growths larger than one centimeter) and roughly 90 percent of early-stage colorectal cancers. These detection rates make the blood test competitive with fecal immunochemical tests (FIT) and superior to stool-based screening for finding polyps before they turn malignant.
The advantage lies partly in simplicity. A nurse draws blood once. Results arrive within days. Patients avoid bowel preparation, sedation, and the discomfort of colonoscopy scope insertion. For people with medical anxiety or mobility limitations, this matters enormously. The test also works for individuals on blood thinners or those with certain gastrointestinal conditions that complicate colonoscopy.
Dr. Heather Hampel, a genetic counselor at Cincinnati Children's Hospital, notes that blood-based screening removes a major barrier to participation. Historically, fear and inconvenience kept millions from screening. Those who test positive on a blood test then proceed to colonoscopy for polyp removal or biopsy. The blood test functions as a gatekeeper, directing resources toward people who genuinely need further investigation.
Limitations exist. The blood test performs less effectively in detecting smaller polyps (less than one centimeter), which rarely progress to cancer but sometimes do. Insurance coverage remains inconsistent. Some plans cover blood-based ctDNA tests; others classify them as experimental. The test costs between $500 and $1,500 without insurance, though that expense diminishes when spread across the five to ten years most people wait between screenings.
The American Cancer Society and U.S. Preventive Services Task Force have begun incorporating blood-based ctDNA tests into colorectal cancer screening guidelines, though colonoscopy remains the gold standard for actually removing polyps. The emergence of this option signals a shift toward personalized screening strategies. People at average risk might start with a blood test, while those with family history or prior polyps still receive colonoscopy as a first-line approach.
Researchers continue refining the technology to improve detection of smaller polyps and to clarify which populations benefit most. Early trials suggest the test may eventually become a primary screening tool rather than solely a backup option. The combination of noninvasive screening followed by targeted colonoscopy could reshape colorectal cancer prevention within the next five years.